Methods to induce targeted protein degradation through bifunctional molecules

Patent metadata

Field	Value
Publication number	US-10125114-B2
Application number	US-201715632023-A
Country	US
Kind code	B2
Filing date	Jun 23, 2017
Priority date	Dec 23, 2014
Publication date	Nov 13, 2018
Grant date	Nov 13, 2018

Abstract

The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.

First claim

We claim:

1. A compound selected from:

or an enantiomer, diastereomer, stereoisomer, or a pharmaceutically acceptable salt thereof, wherein:
Y is a bond, (CH 2 ) 1-6 , (CH 2 ) 0-6 —O, (CH 2 ) 0-6 —C(O)NR 2 ′, (CH 2 ) 0-6 —NR 2 ′C(O), (CH 2 ) 0-6 —NH, or (CH 2 ) 0-6 —NR 2 ;
X is C(O) or C(C 1 -C 3 alkyl) 2 ;
m is 0, 1, 2 or 3;
n is 0, 1 or 2;
wherein at least one of the following is present:
a. X is C(C 1 -C 3 alkyl) 2 ; or
b. m is 1, 2, or 3; or
c. n is 1 or 2;

each R 1 is C 1 -C 6 alkoxy;
R 2 is C 1 -C 6 alkyl, C(O)—C 1 -C 6 alkyl, or C(O)—C 3 -C 6 cycloalkyl;
R 2 ′ is H or C 1 -C 6 alkyl;
R 3 is H or C 1 -C 3 alkyl;
each R 3 ′ is independently C 1 -C 3 alkyl;
each R 4 is independently H or C 1 -C 3 alkyl; or two R 4 , together with the carbon atom to which they are attached, form a C(O), a C 3 -C 6 carbocycle, or a 4-, 5-, or 6-membered heterocycle comprising 1 or 2 heteroatoms selected from N and O;
R 5 is H, deuterium, C 1 -C 3 alkyl, R or Cl;
the Linker is

each W is independently absent, CH 2 , O, S, NH or NR 5 ;
Z is absent, CH 2 , O, NH or NR 5 ;
Q is absent or —CH 2 C(O)NH—;
p1 is selected from 0, 1, 2, 3, 4, 5, and 6;
p2 is selected from 0, 1, 2, 3, 4, 5, and 6;
p3 is selected from 1, 2, 3, 4, and 5;
Targeting Ligand is selected from:

wherein:
T 6 is CRb 4 or N;
Rb 1 , Rb 2 , and Rb 5 are each independently H or C 1 -C 3 alkyl;
Rb 3 is C 3 -C 6 cycloalkyl;
each Rb 4 is independently H, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, CN, or halogen;
nn3 is 0, 1, 2, or 3;
each Rb 6 is independently C 1 -C 3 alkyl, C 1 -C 3 alkoxy, CN, or halogen;
Rb 7 is C(O)NRb 8 L, OL, NRb 8 L, or L;
Rb 8 is H or C 1 -C 3 alkyl;
each Rd 1 is independently H or C 1 -C 3 alkyl;
nn6 is 0, 1, 2, or 3;
nn7 is 0, 1, 2, or 3;
each Rd 2 is independently C 1 -C 3 alkyl, C 1 -C 3 alkoxy, CN, or halogen;
Rd 3 is C(O)NRd 4 L, OL, NRd 4 L, or L;
Rd 4 is H or C 1 -C 3 alkyl;
each Re 1 is independently H or C 1 -C 3 alkyl;
nn8 is 0, 1, 2, or 3;
nn9 is 0, 1, 2, or 3;
each Re 2 is independently C 1 -C 3 alkyl, C 1 -C 3 alkoxy, CN, or halogen;
Re 3 is NH—(CH 2 ) 1-3 —C(O)NRe 4 L, C(O)NRe 4 L, OL, NRe 4 L, or L;
Re 4 is H or C 1 -C 3 alkyl;
each Rh 1 is independently H or C 1 -C 3 alkyl;
nn12 is 0, 1, 2, or 3;
each Rh 2 is independently C 1 -C 3 alkyl, C 1 -C 3 alkoxy, CN, or halogen;
Rh 3 is C(O)L or C(O)—(CH 2 ) 1-3 —C(O)NRh 6 L;
Rh 6 is H or C 1 -C 3 alkyl;
Rh 4 is H or C 1 -C 3 alkyl;
Rh 5 is C 1 -C 6 alkyl; and
L is the attachment point to the Linker.

2. The compound of claim 1 wherein X is C(CH 3 ) 2 .

3. The compound of claim 1 , wherein X is C(CH 2 CH 3 ) 2 .

4. The compound of claim 1 , wherein R 5 is H or deuterium.

5. The compound of claim 1 , wherein each R 1 is independently selected from methoxy, ethoxy, and propoxy.

6. The compound of claim 1 , wherein m is 0.

7. The compound of claim 1 , wherein m is 1.

8. The compound of claim 1 , wherein n is 0.

9. The compound of claim 1 , wherein each R 1 is independently methoxy, ethoxy, or propoxy.

10. The compound of claim 1 , wherein the Targeting Ligand is:

11. The compound of claim 1 , wherein the Targeting Ligand is:

12. The compound of claim 1 , wherein the Targeting Ligand is:

13. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

14. A method of treating a BRD4 mediated cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 .

15. A compound selected from:

or a pharmaceutically acceptable salt thereof.

16. The compound of claim 15 selected from:

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 15 selected from:

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 15 selected from:

or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 15 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

20. A method of treating a BRD4 mediated cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 15 .

Assignees

• Dana Farber Cancer Inst Inc

Inventors

• Bradner James
• Buckley Dennis
• Winter Georg

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D471/14

  Ortho-condensed systems · CPC title

• C07D475/00

  Heterocyclic compounds containing pteridine ring systems · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title